DDInter1840 DDInter448
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements.
Trabectedin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Crizotinib
Trabectedin {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Crizotinib
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Trabectedin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) covaries with {v} (Gene) PTK2B
PTK2B {u} (Gene) is bound by {v} (Compound) Crizotinib
Trabectedin {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Crizotinib
Trabectedin {u} (Compound) causes {v} (Side Effect) Pulmonary embolism
Pulmonary embolism {u} (Side Effect) is caused by {v} (Compound) Cyclophosphamide
Cyclophosphamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Crizotinib
Trabectedin {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Zafirlukast
Zafirlukast {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Crizotinib
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is associated with {v} (Disease) lung cancer
lung cancer {u} (Disease) is treated by {v} (Compound) Crizotinib
Trabectedin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) interacts with {v} (Gene) STUB1
STUB1 {u} (Gene) is downregulated by {v} (Compound) Crizotinib
Trabectedin {u} (Compound) causes {v} (Side Effect) Peripheral sensory neuropathy
Peripheral sensory neuropathy {u} (Side Effect) is caused by {v} (Compound) Carfilzomib
Carfilzomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Crizotinib
Trabectedin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Trabectedin (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Crizotinib (Compound)
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is bound by Crizotinib (Compound) and SRC (Gene) is upregulated by Crizotinib (Compound)
Trabectedin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) covaries with PTK2B (Gene) and PTK2B (Gene) is bound by Crizotinib (Compound)
Trabectedin (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Trabectedin (Compound) causes Pulmonary embolism (Side Effect) and Pulmonary embolism (Side Effect) is caused by Cyclophosphamide (Compound) and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Trabectedin (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Zafirlukast (Compound) and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is associated with lung cancer (Disease) and lung cancer (Disease) is treated by Crizotinib (Compound)
Trabectedin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) interacts with STUB1 (Gene) and STUB1 (Gene) is downregulated by Crizotinib (Compound)
Trabectedin (Compound) causes Peripheral sensory neuropathy (Side Effect) and Peripheral sensory neuropathy (Side Effect) is caused by Carfilzomib (Compound) and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib